TABLE I.
Baseline characteristics for all participants in the study stratified by clinical asthma remission status (n = 879)
| No asthma remission (n = 650) | Asthma remission (n = 229) | P value | |
|---|---|---|---|
| Baseline age (y), mean ± SD | 8.8 ± 2.1 | 8.6 ± 1.9 | .07 |
| Age at asthma diagnosis (y), mean ± SD | 3.8 ± 2.5 | 4.1 ± 2.5 | .07 |
| Sex | .001 | ||
| Male | 407 (62.6%) | 115 (50.2%) | |
| Female | 243 (37.4%) | 114 (49.8%) | |
| Ethnicity | .90 | ||
| White | 450 (69.2%) | 154 (67.2%) | |
| Black | 89 (13.7%) | 35 (15.3%) | |
| Hispanic | 57 (8.8%) | 22 (9.6%) | |
| Other | 54 (8.3%) | 18 (7.9%) | |
| Baseline household income (USD) | .95 | ||
| <$29,999 | 140 (22.3%) | 48 (22.3%) | |
| $30,000–$49,999 | 215 (34.2%) | 71 (33.0%) | |
| ≥$50,000 | 274 (43.6%) | 96 (44.7%) | |
| Parental highest education | .38 | ||
| High school or less | 116 (17.8%) | 35 (15.3%) | |
| Some college or higher | 534 (82.2%) | 194 (84.7%) | |
| CAMP treatment group | .15 | ||
| Budesonide | 178 (27.4%) | 78 (34.1%) | |
| Nedocromil | 204 (31.4%) | 63 (27.5%) | |
| Placebo | 268 (41.2%) | 88 (38.4%) | |
| Parental history of asthma | 270 (44.3%) | 94 (45.2%) | .82 |
| Body mass index (kg/m2), mean ± SD | 18.2 ± 3.6 | 17.9 ± 3.1 | .33 |
| Wheezes with colds | 601 (92.6%) | 199 (86.9%) | .009 |
| Wheezes apart from colds | 524 (80.7%) | 168 (73.4%) | .02 |
| Exacerbations after exercise | 527 (81.1%) | 164 (71.9%) | .004 |
| Aeroallergen sensitization on skin testing | 584 (89.8%) | 190 (83.0%) | .006 |
| History of physician-diagnosed allergies | 445 (68.5%) | 152 (66.4%) | .56 |
| Exposure to home tobacco smoke | 256 (39.6%) | 97 (42.7%) | .45 |
| Baseline asthma severity | .01 | ||
| Mild | 296 (45.5%) | 117 (55.5%) | |
| Moderate | 354 (54.5%) | 102 (44.5%) | |
| Baseline PC20 (mg/mL), median ± IQR | 0.9 ± 1.6 | 1.7 ± 3.6 | <.001 |
| Baseline FEV1 (% predicted), mean ± SD | 92.2 ± 14.1 | 99.0 ± 12.7 | <.001 |
| Baseline FEV1/FVC ratio (%), mean ± SD | 77.9 ± 7.9 | 85.6 ± 6.3 | <.001 |
| Baseline serum IgE level (ng/mL), median ± IQR | 516.0 ± 1166.0 | 343.0 ± 924.5 | <.001 |
| Baseline eosinophil count (cells/mL), median ± IQR | 422.0 ± 493.5 | 320.5 ± 327.3 | <.001 |
| Atopic dermatitis | 145 (76.7%) | 44 (74.6%) | .74 |
| Mother smoked while pregnant | 90 (13.9%) | 31 (13.5%) | .88 |
| Used wood stove for heating or cooking | 67 (10.3%) | 16 (7.0%) | .14 |
| Pet ownership | 51 (7.8%) | 12 (5.2%) | .19 |
| Clinic site | .06 | ||
| Albuquerque | 77 (11.8%) | 23 (10.0%) | |
| Baltimore | 75 (11.5%) | 33 (14.4%) | |
| Boston | 73 (11.2%) | 39 (17.0%) | |
| Denver | 90 (13.8%) | 19 (8.3%) | |
| San Diego | 70 (10.8%) | 27 (11.8%) | |
| Seattle | 91 (14.0%) | 32 (14.0%) | |
| St Louis | 101 (15.5%) | 25 (10.9%) | |
| Toronto | 73 (11.2%) | 31 (13.5%) |
IQR, Interquartile range.